Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma

• Published in: Haematologica (Roma) Vol. 107; no. 12; pp. 2928 - 2943
• Main Authors: Madugula, Kiran K, Joseph, Julie, DeMarino, Catherine, Ginwala, Rashida, Teixeira, Vanessa, Khan, Zafar K, Sales, Dominic, Wilson, Sydney, Kashanchi, Fatah, Rushing, Amanda W, Lemasson, Isabelle, Harhaj, Edward W, Janakiram, Murali, Ye, B Hilda, Jain, Pooja
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01-12-2022; Ferrata Storti Foundation
• Subjects: Animals; Human T-lymphotropic virus 1 - genetics; Human T-lymphotropic virus 1 - metabolism; Humans; Leukemia-Lymphoma, Adult T-Cell - pathology; Lymphoma - genetics; MEF2 Transcription Factors - genetics; MEF2 Transcription Factors - metabolism; Mice; Promoter Regions, Genetic; T-cell Leukemia/lymphoma; Viral Proteins - genetics; Viral Proteins - metabolism
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2021.279542

Adult T-cell leukemia and lymphoma (ATLL) is an intractable T-cell neoplasia caused by a retrovirus, namely human T-cell leukemia virus type 1 (HTLV-1). Patients suffering from ATLL present a poor prognosis and have a dearth of treatment options. In contrast to the sporadic expression of viral transactivator protein Tax present at the 5' promoter region long terminal repeats (LTR), HTLV-1 bZIP gene (HBZ) is encoded by 3'LTR (the antisense promoter) and maintains its constant expression in ATLL cells and patients. The antisense promoter is associated with selective retroviral gene expression and has been an understudied phenomenon. Herein, we delineate the activity of transcription factor MEF (myocyte enhancer factor)-2 family members, which were found to be enriched at the 3'LTR and play an important role in the pathogenesis of ATLL. Of the four MEF isoforms (A to D), MEF-2A and 2C were highly overexpressed in a wide array of ATLL cell lines and in acute ATLL patients. The activity of MEF-2 isoforms were determined by knockdown experiments that led to decreased cell proliferation and regulated cell cycle progression. High enrichment of MEF-2C was observed at the 3'LTR along with cofactors Menin and JunD resulting in binding of MEF-2C to HBZ at this region. Chemical inhibition of MEF-2 proteins resulted in the cytotoxicity of ATLL cells in vitro and reduction of proviral load in a humanized mouse model. Taken together, this study provides a novel mechanism of 3'LTR regulation and establishes MEF-2 signaling a potential target for therapeutic intervention for ATLL.